{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:16:41Z","timestamp":1792844201571,"version":"4.5.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>In recent years, the use of chimeric antigen receptor (CAR)-T cells has emerged as a promising immunotherapy in multiple diseases. CAR-T cells are T cells genetically modified to express a surface receptor, known as CAR, for the targeting of cognate antigens on specific cells. The effectiveness of CAR-T cell therapy in hematologic malignancies including leukemia, myeloma, and non-Hodgkin\u2019s lymphoma has led to consider its use as a potential avenue of treatment for autoimmune diseases. However, broadening the use of CAR-T cell therapy to a large spectrum of autoimmune conditions is challenging particularly because of the possible development of side effects including cytokine release syndrome and neurotoxicity. The design of CAR therapy that include additional immune cells such as double-negative T cells, \u03b3\u03b4 T cells, T regulatory cells and natural killer cells has shown promising results in preclinical studies and clinical trials in oncology, suggesting a similar potential utility in the treatment of autoimmune diseases. This review examines the mechanisms, efficacy, and safety of CAR approaches with a focus on their use in autoimmune diseases including systemic lupus erythematosus, Sj\u00f6gren\u2019s syndrome, systemic sclerosis, multiple sclerosis, myasthenia gravis, lupus nephritis and other autoimmune diseases. Advantages and disadvantages as compared to CAR-T cell therapy will also be discussed.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1461102","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T04:31:53Z","timestamp":1727757113000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["CAR immunotherapy in autoimmune diseases: promises and challenges"],"prefix":"10.3389","volume":"15","author":[{"given":"Jingjing","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanjing","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"La Cava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663201","article-title":"Reactions related to CAR-T cell therapy","volume":"12","author":"Miao","year":"2021","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.2072","article-title":"Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma","volume":"3","author":"Lyman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.12.004","article-title":"T cell development: old tales retold by single-cell RNA sequencing","volume":"42","author":"Liu","year":"2021","journal-title":"Trends Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2583","article-title":"Isolation and characterization of human antigen-specific TCR \u03b1\u03b2+ CD4-CD8- double-negative regulatory T cells","volume":"105","author":"Fischer","year":"2005","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.149.3.808","article-title":"Different subsets of T cells in the adult mouse bone marrow and spleen induce or suppress acute graft-versus-host disease","volume":"149","author":"Palathumpat","year":"1992","journal-title":"J Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018080815","article-title":"Activation and proliferation of PD-1+ kidney double-negative T cells is dependent on nonclassical MHC proteins and IL-2","volume":"30","author":"Sadasivam","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020029","article-title":"The immune regulatory function of lymphoproliferative double negative T cells in vitro and in vivo","volume":"196","author":"Ford","year":"2002","journal-title":"J Exp Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13046-018-0756-9","article-title":"Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy","volume":"37","author":"Chen","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028480","article-title":"Interferon \u03b3 and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity","volume":"11","author":"Alspach","year":"2019","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.99","article-title":"Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy","volume":"25","author":"Merims","year":"2011","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2228","article-title":"Allogeneic human double negative T cells as a novel immunotherapy for acute myeloid leukemia and its underlying mechanisms","volume":"24","author":"Lee","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201040982","article-title":"Characterization of the immunoregulatory function of human TCR-\u03b1\u03b2+ CD4- CD8- double-negative T cells","volume":"41","author":"Voelkl","year":"2011","journal-title":"Eur J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00883","article-title":"Human double-negative regulatory T-cells induce a metabolic and functional switch in effector T-cells by suppressing mTOR activity","volume":"10","author":"Haug","year":"2019","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000778","article-title":"Double-negative T cells in autoimmune diseases","volume":"33","author":"Li","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1006\/clim.2002.5225","article-title":"A composite picture of TcR \u03b1\u03b2+ CD4-CD8- T Cells (\u03b1\u03b2-DNTCs) in humans with autoimmune lymphoproliferative syndrome","volume":"104","author":"Bleesing","year":"2002","journal-title":"Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2015.01.006","article-title":"A77 1726, the active metabolite of leflunomide, attenuates lupus nephritis by promoting the development of regulatory T cells and inhibiting IL-17-producing double negative T cells","volume":"157","author":"Qiao","year":"2015","journal-title":"Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12967-024-05132-8","article-title":"Double-negative T cells ameliorate psoriasis by selectively inhibiting IL-17A-producing \u03b3\u03b4low T cells","volume":"22","author":"Wei","year":"2024","journal-title":"J Transl Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/77513","article-title":"Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression","volume":"6","author":"Zhang","year":"2000","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl3642","article-title":"Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities","volume":"7","author":"Vasic","year":"2022","journal-title":"Sci Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13145","article-title":"Infusion of ex-vivo expanded human TCR-\u03b1\u03b2+ double-negative regulatory T cells delays onset of xenogeneic graft-versus-host disease","volume":"193","author":"Achita","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"102516","DOI":"10.1016\/j.eclinm.2024.102516","article-title":"CD19-CAR-DNT cells (RJMty19) in patients with relapsed or refractory large B-cell lymphoma: a phase 1, first-in-human study","author":"Xiao","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2741\/3247","article-title":"Natural tregs and autoimmunity","volume":"14","author":"La Cava","year":"2009","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/ni.1818","article-title":"Regulatory T cells exert checks and balances on self tolerance and autoimmunity","volume":"11","author":"Wing","year":"2010","journal-title":"Nat Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0120-4","article-title":"Regulatory T cells in autoimmune disease","volume":"19","author":"Dominguez-Villar","year":"2018","journal-title":"Nat Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.06.001","article-title":"First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells","volume":"133","author":"Trzonkowski","year":"2009","journal-title":"Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"104216","DOI":"10.1016\/j.cellimm.2020.104216","article-title":"CD4+ T cells engineered with FVIII-CAR and murine Foxp3 suppress anti-factor VIII immune responses in hemophilia a mice","volume":"358","author":"Fu","year":"2020","journal-title":"Cell Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040139","article-title":"In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes","volume":"199","author":"Tang","year":"2004","journal-title":"J Exp Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"83ra42","DOI":"10.1126\/scitranslmed.3002076","article-title":"Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells","volume":"3","author":"Sagoo","year":"2011","journal-title":"Sci Transl Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI82771","article-title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","volume":"126","author":"MacDonald","year":"2016","journal-title":"J Clin Invest"},{"key":"B33","article-title":"Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells","volume":"5","author":"Mezzanzanica","year":"1998","journal-title":"Cancer Gene Ther"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1038\/s41467-024-46448-9","article-title":"Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus","volume":"15","author":"Doglio","year":"2024","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.41","article-title":"Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells","volume":"22","author":"Blat","year":"2014","journal-title":"Mol Ther"},{"key":"B37","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflamm"},{"key":"B38","doi-asserted-by":"publisher","first-page":"104222","DOI":"10.1016\/j.cellimm.2020.104222","article-title":"Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression","volume":"358","author":"De Paula Pohl","year":"2020","journal-title":"Cell Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"102289","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J Autoimmun"},{"key":"B40","doi-asserted-by":"publisher","first-page":"109328","DOI":"10.1016\/j.clim.2023.109328","article-title":"Manufacturing regulatory T cells for adoptive cell therapy in immune diseases: A critical appraisal","volume":"251","author":"Abhishek","year":"2023","journal-title":"Clin Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0903158107","article-title":"Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus","volume":"107","author":"Humrich","year":"2010","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12967-017-1378-2","article-title":"\u03b3\u03b4 T cells: friend or foe in cancer development","volume":"16","author":"Zhao","year":"2018","journal-title":"J Transl Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-011-0706-6","article-title":"\u03b3\u03b4 T-APCs: a novel tool for immunotherapy","volume":"68","author":"Moser","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nri3384","article-title":"Six-of-the-best: unique contributions of \u03b3\u03b4 T cells to immunology","volume":"13","author":"Vantourout","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.267","article-title":"Bispecific T-cells expressing polyclonal repertoire of endogenous \u03b3\u03b4 T-cell receptors and introduced CD19-specific chimeric antigen receptor","volume":"21","author":"Deniger","year":"2013","journal-title":"Mol Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01347","article-title":"Gamma-delta CAR-T cells show CAR-directed and independent activity against leukemia","volume":"11","author":"Rozenbaum","year":"2020","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.12.001","article-title":"Chimeric antigen receptor-engineered human \u03b3\u03b4 T cells: enhanced cytotoxicity with retention of cross presentation","volume":"26","author":"Capsomidis","year":"2018","journal-title":"Mol Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.601272","article-title":"CD73+ Dendritic cells in cascading th17 responses of experimental autoimmune uveitis-induced mice","volume":"11","author":"Ko","year":"2020","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.molimm.2021.02.023","article-title":"Augmented Th17-stimulating activity of BMDCs as a result of reciprocal interaction between \u03b3\u03b4 and dendritic cells","volume":"134","author":"Sun","year":"2021","journal-title":"Mol Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/ana.410300608","article-title":"Peripheral blood \u03b3\u03b4 T cells lyse fresh human brain-derived oligodendrocytes","volume":"30","author":"Freedman","year":"1991","journal-title":"Ann Neurol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jneuroim.2018.02.009","article-title":"Characterization of circulating \u03b3\u03b4 T cells in relapsing vs remission multiple sclerosis","volume":"318","author":"Monteiro","year":"2018","journal-title":"J Neuroimmunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.12932\/AP0733","article-title":"Regulatory T, natural killer T and \u03b3\u03b4 T cells in multiple sclerosis and chronic fatigue syndrome\/myalgic encephalomyelitis: a comparison","volume":"34","author":"Ramos","year":"2016","journal-title":"Asian Pac J Allergy Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.8.4678","article-title":"\u03b3\u03b4 T cells regulate the extent and duration of inflammation in the central nervous system by a Fas ligand-dependent mechanism","volume":"174","author":"Ponomarev","year":"2005","journal-title":"J Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ni1581","article-title":"Up on the tightrope: natural killer cell activation and inhibition","volume":"9","author":"Lanier","year":"2008","journal-title":"Nat Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1172\/JCI90387","article-title":"CD56bright NK cells exhibit potent antitumor responses following IL-15 priming","volume":"127","author":"Wagner","year":"2017","journal-title":"J Clin Invest"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.10.3146","article-title":"Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset","volume":"97","author":"Cooper","year":"2001","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2018.12.003","article-title":"The emergence of natural killer cells as a major target in cancer immunotherapy","volume":"40","author":"Souza-Fonseca-Guimaraes","year":"2019","journal-title":"Trends Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: A promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"B60","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2007.02573.x","article-title":"In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection","volume":"121","author":"Zhang","year":"2007","journal-title":"Immunology"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.04.006","article-title":"La\/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease","volume":"192","author":"Meng","year":"2018","journal-title":"Clin Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"100009","DOI":"10.1016\/j.xcrm.2020.100009","article-title":"CAR NK cell therapy for T follicular helper cells","volume":"1","author":"King","year":"2020","journal-title":"Cell Rep Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"key":"B66","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am J Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1461102\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T04:31:54Z","timestamp":1727757114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1461102\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":66,"alternative-id":["10.3389\/fimmu.2024.1461102"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1461102","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"article-number":"1461102"}}